Sure. The most compelling patent provisions and IP protection provisions relate to the pharmaceutical industry rather than our industry. However, because of the prolific nature of our IP production not just in the Canadian operation, but also in our other research centres in the United States, India, and France, the provisions around IP protection and any provisions around intellectual property are of significant importance to my company.
Again, one of the things that we're trying to facilitate.... As a multinational corporation we succeed when we can leverage skill and scale across our entire organization, but the propensity for us to make foreign direct investments in IP creation that might be at risk is going to be reduced. This is one of the reasons we're always so concerned about this notion of IP protection, whether it be in multilateral or plurilateral instruments or in the domestic framework. We've given testimony to your colleagues on the industry committee and submitted content to the Department of Industry as well in that regard.
IP protection provisions as they relate to a multilateral instrument like the CETA are of compelling importance, and indeed, the lifeblood of being able to commercialize and monetize the knowledge work that we do right here in Canada and at our other locations around the world.